Physician profile
Stephen Tester
NPI 1710654421
$4,253.80
in general payments reported to CMS, 2019-2025
7 companies · $1,131 in 2025
The $1,131 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.05 · 2022: $1,158 · 2023: $910 · 2024: $1,026 · 2025: $1,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,066.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,840.02 | 2022-2025 | Total30, Precision7, Precision 1 |
| Bausch & Lomb Americas INC. | $1,098.11 | 2022-2025 | Infuse, Xiidra, Miebo |
| Coopervision INC. | $819.20 | 2022-2025 | Myday Contact Lens, Clariti Contact Lens |
| Johnson & Johnson Vision Care, INC. | $367.43 | 2022-2024 | Acuvue |
| Rxsight INC | $57.86 | 2022 | |
| Glaukos Corporation | $42.13 | 2024 | Photrexa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $29.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Tester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.